DK0991409T3 - Farmaceutiske tiagabinindeholdende præparater med reguleret frigivelse - Google Patents

Farmaceutiske tiagabinindeholdende præparater med reguleret frigivelse

Info

Publication number
DK0991409T3
DK0991409T3 DK98937738T DK98937738T DK0991409T3 DK 0991409 T3 DK0991409 T3 DK 0991409T3 DK 98937738 T DK98937738 T DK 98937738T DK 98937738 T DK98937738 T DK 98937738T DK 0991409 T3 DK0991409 T3 DK 0991409T3
Authority
DK
Denmark
Prior art keywords
hours
controlled release
tiagabine
tenagabine
containing preparations
Prior art date
Application number
DK98937738T
Other languages
Danish (da)
English (en)
Inventor
Maurice Joseph Anthony Clancy
Michelle Caulfield
Kenneth Iain Cumming
Original Assignee
Elan Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26320083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0991409(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IE19970588A external-priority patent/IE970588A1/en
Application filed by Elan Corp Plc filed Critical Elan Corp Plc
Application granted granted Critical
Publication of DK0991409T3 publication Critical patent/DK0991409T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DK98937738T 1997-08-01 1998-07-30 Farmaceutiske tiagabinindeholdende præparater med reguleret frigivelse DK0991409T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5443297P 1997-08-01 1997-08-01
IE19970588A IE970588A1 (en) 1997-08-01 1997-08-08 Controlled release pharmaceutical compositions containing tiagabine
PCT/IE1998/000067 WO1999006045A1 (en) 1997-08-01 1998-07-30 Controlled release pharmaceutical compositions containing tiagabine

Publications (1)

Publication Number Publication Date
DK0991409T3 true DK0991409T3 (da) 2002-03-25

Family

ID=26320083

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98937738T DK0991409T3 (da) 1997-08-01 1998-07-30 Farmaceutiske tiagabinindeholdende præparater med reguleret frigivelse

Country Status (10)

Country Link
EP (1) EP0991409B1 (https=)
JP (1) JP2001511450A (https=)
AT (1) ATE212550T1 (https=)
AU (1) AU8643698A (https=)
CA (1) CA2299464C (https=)
DE (1) DE69803670T2 (https=)
DK (1) DK0991409T3 (https=)
ES (1) ES2172179T3 (https=)
PT (1) PT991409E (https=)
WO (1) WO1999006045A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002325404B2 (en) * 1998-01-22 2006-02-02 Abbott Laboratories Extended Release Tiagabine Formulations with Reduced Side-effects
ZA99407B (en) * 1998-01-22 1999-07-20 Abbott Lab Extended release tiagabine formulations with reduced side-effects.
RU2220715C2 (ru) * 1999-08-04 2004-01-10 Яманоути Фармасьютикал Ко., Лтд. Стабильная пероральная, образующая гидрогель, фармацевтическая композиция, способ ее получения, способ предотвращения изменений высвобождения лекарственного средства, способ увеличения физической стабильности пероральной композиции
KR100510270B1 (ko) * 2002-11-29 2005-08-26 센츄론(주) 펠렛타이저를 이용한 서방성 제제의 제조방법
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
WO2004082615A2 (en) * 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK288385D0 (da) * 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5750140A (en) * 1994-05-20 1998-05-12 Novo Nordisk A/S Transdermal delivery of tiagabine
MX9708394A (es) * 1995-05-05 1998-02-28 Novo Nordisk As Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
EP0912091B1 (en) * 1996-05-24 2007-12-19 Smithkline Beecham Corporation Use of gaba uptake inhibitors as anti-tussive agents
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders

Also Published As

Publication number Publication date
EP0991409A1 (en) 2000-04-12
EP0991409B1 (en) 2002-01-30
CA2299464C (en) 2009-02-17
WO1999006045A1 (en) 1999-02-11
DE69803670D1 (de) 2002-03-14
AU8643698A (en) 1999-02-22
DE69803670T2 (de) 2002-11-21
JP2001511450A (ja) 2001-08-14
PT991409E (pt) 2002-06-28
CA2299464A1 (en) 1999-02-11
ES2172179T3 (es) 2002-09-16
ATE212550T1 (de) 2002-02-15

Similar Documents

Publication Publication Date Title
DK0688214T3 (da) Fremgangsmåder til inhibering af knogletab med 3,4-diarylchroman
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
MY115662A (en) Novel compounds with analgesic effect
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
AP1637A (en) Celecoxib compositions.
EP1428821A8 (en) Piperidin-4-yl amines with analgesic effect
NO971206D0 (no) Forlenget-frigjöringsformulering
PL309721A1 (en) Pharmaceutical composition containing fluoxetin hydrochloride
WO2002038171A3 (en) METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
YU49202A (sh) Benzazolski derivati i njihova upotreba kao modulatora jnk
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
ATE305473T1 (de) Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
ES2147788T3 (es) 3,4-diarilcromanos para el tratamiento de la dermatitis.
DK0991409T3 (da) Farmaceutiske tiagabinindeholdende præparater med reguleret frigivelse
FI933975A0 (fi) Tabletter som kontrollerat avgiver naproxen
NO982863L (no) Nye forbindelser med analgetisk effekt
BR0014440A (pt) Formulações de liberação controlada oral
BG103512A (en) Substituted pyramidine compounds and their application
BRPI0415546A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
AU1400895A (en) 2,3-diaryl-1-benzopyrans for treating dermatitis
YU24603A (sh) Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin